Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Preclinical study supports clinical trial of Affimed NK cells, MD Anderson says » 15:53
05/13/21
05/13
15:53
05/13/21
15:53
AFMD

Affimed

$8.86 /

-0.275 (-3.01%)

Cytokine-activated…

Cytokine-activated natural killer, or NK, cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center. Affimed's AFM13 is a proprietary bispecific antibody designed to bind to CD16a on NK cells and CD30 on lymphoma cells. The findings were published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, the center reported. Senior author Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy, said, "This preclinical work provided proof of principle for NK cells precomplexed with AFM13, suggesting that they can effectively eliminate lymphoma cells expressing CD30 and warrant further clinical testing." Reference Link

ShowHide Related Items >><<
AFMD Affimed
$8.86 /

-0.275 (-3.01%)

AFMD Affimed
$8.86 /

-0.275 (-3.01%)

04/12/21 BMO Capital
Affimed price target raised to $15 from $12 at BMO Capital
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
  • 13
    Jan
AFMD Affimed
$8.86 /

-0.275 (-3.01%)

Over a month ago
Hot Stocks
Xoma adds three Affimed ICE programs to royalty portfolio » 09:14
04/15/21
04/15
09:14
04/15/21
09:14
XOMA

Xoma

$37.39 /

-0.175 (-0.47%)

, AFMD

Affimed

$10.33 /

+0.465 (+4.71%)

XOMA Corporation (XOMA)…

XOMA Corporation (XOMA) announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (AFMD) innate cell engager programs for which XOMA could receive future economics. In 2006, Affimed licensed certain XOMA technologies to further its research and discovery efforts. AFM13, which has Orphan Drug designation from the U.S. Food and Drug Administration, is a first-in-class CD30/CD16A ICE generated from Affimed's ROCK platform that induces specific and selective killing of CD30-positive tumor cells by engaging and activating natural killer cells and macrophages, thereby leveraging the power of the body's own innate immune system. Affimed currently is studying AFM13 in combination with cord blood-derived allogeneic natural killer cells in cooperation with the MD Anderson Cancer Center in Houston. AFM24 is a tetravalent, bispecific EGFR- and CD16A-binding ICE also generated from Affimed's ROCK platform. AFM24 uses the cytotoxic potential of the innate immune system by redirecting and activating NK cells and macrophages to kill EGFR-positive cancer cells through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, respectively. XOMA is eligible to receive undisclosed payments on future commercial sales of each of the three ICE molecules and any pre-loaded NK cells containing the ICE molecules. Additionally, XOMA is eligible to receive an undisclosed milestone for each program on achieving marketing approval.

ShowHide Related Items >><<
XOMA Xoma
$37.39 /

-0.175 (-0.47%)

AFMD Affimed
$10.33 /

+0.465 (+4.71%)

XOMA Xoma
$37.39 /

-0.175 (-0.47%)

01/19/21 H.C. Wainwright
Xoma price target raised to $56 from $30 at H.C. Wainwright
AFMD Affimed
$10.33 /

+0.465 (+4.71%)

04/12/21 BMO Capital
Affimed price target raised to $15 from $12 at BMO Capital
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
XOMA Xoma
$37.39 /

-0.175 (-0.47%)

  • 13
    Jan
AFMD Affimed
$10.33 /

+0.465 (+4.71%)

Hot Stocks
Ridgeback Capital reports 5.5% passive stake in Affimed » 16:31
04/14/21
04/14
16:31
04/14/21
16:31
AFMD

Affimed

$10.33 /

+0.465 (+4.71%)

Ridgeback Capital…

Ridgeback Capital disclosed a 5.5% stake in Affimed, which represents 6.45M shares. The filing does not allow for activism.

ShowHide Related Items >><<
AFMD Affimed
$10.33 /

+0.465 (+4.71%)

AFMD Affimed
$10.33 /

+0.465 (+4.71%)

04/12/21 BMO Capital
Affimed price target raised to $15 from $12 at BMO Capital
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
  • 13
    Jan
AFMD Affimed
$10.33 /

+0.465 (+4.71%)

Conference/Events
Affimed to hold a conference call » 15:55
04/14/21
04/14
15:55
04/14/21
15:55
AFMD

Affimed

$10.28 /

+0.41 (+4.16%)

Management discusses the…

Management discusses the data presented at the AACR Annual Meeting on a conference call to be held on April 14 at 4:05 pm. Webcast Link

ShowHide Related Items >><<
AFMD Affimed
$10.28 /

+0.41 (+4.16%)

AFMD Affimed
$10.28 /

+0.41 (+4.16%)

04/12/21 BMO Capital
Affimed price target raised to $15 from $12 at BMO Capital
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
  • 13
    Jan
AFMD Affimed
$10.28 /

+0.41 (+4.16%)

Conference/Events
Affimed to hold a conference call » 04:55
04/14/21
04/14
04:55
04/14/21
04:55
AFMD

Affimed

$9.87 /

+0.225 (+2.33%)

Management discusses the…

Management discusses the data presented at the AACR Annual Meeting on a conference call to be held on April 14 at 4:05 pm. Webcast Link

ShowHide Related Items >><<
AFMD Affimed
$9.87 /

+0.225 (+2.33%)

AFMD Affimed
$9.87 /

+0.225 (+2.33%)

04/12/21 BMO Capital
Affimed price target raised to $15 from $12 at BMO Capital
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
  • 13
    Jan
AFMD Affimed
$9.87 /

+0.225 (+2.33%)

Recommendations
Affimed price target raised to $15 from $12 at BMO Capital » 07:05
04/12/21
04/12
07:05
04/12/21
07:05
AFMD

Affimed

$9.72 /

+1.85 (+23.51%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim raised the firm's price target on Affimed to $15 from $12 and keeps an Outperform rating on the shares. The analyst is updating his model with Hodgkin lymphoma indication probability of success increasing to 60% from 35% after the positive update from the MD Anderson Cancer Center study, with early responses confirming AFM13+cbNK cell benefit in highly refractory HL patients. The data validates Affimed's recent collaborations with NK cell companies, NKGen and Artiva, Kim tells investors in a research note.

ShowHide Related Items >><<
AFMD Affimed
$9.72 /

+1.85 (+23.51%)

AFMD Affimed
$9.72 /

+1.85 (+23.51%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
  • 13
    Jan
AFMD Affimed
$9.72 /

+1.85 (+23.51%)

Hot Stocks
Affimed highlights potential of Innate Cell Engager AFM24 at AACR » 06:35
04/12/21
04/12
06:35
04/12/21
06:35
AFMD

Affimed

$9.72 /

+1.85 (+23.51%)

Affimed announces…

Affimed announces pre-clinical data on its Innate Cell Engager AFM24 as monotherapy and in combination with adoptively transferred NK cells at the American Association for Cancer Research Virtual Annual Meeting. AFM24, an EGFR/CD16A-binding ICE, mediates antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis and has the potential to overcome toxicity and resistance hurdles associated with current EGFR signaling inhibitors through its differentiated mechanism of action. AFM24 induces NK cell-mediated ADCC against EGFR-expressing tumor cells even in the presence of competing IgG and can induce potent cell killing in tumors independent of KRAS mutations. In addition, data from a xenograft mouse model demonstrate that AFM24 in combination with adoptively transferred NK cells results in dose-dependent tumor regression. "AFM24's novel mechanism of action is independent of EGFR signaling and has the potential to change the treatment paradigm for EGFR-expressing solid tumors," said Dr. Arndt Schottelius, Affimed's Chief Scientific Officer. "Demonstrating that AFM24, in combination with NK cells, shows tumor regression in vivo is an important pre-clinical proof of concept. Combination therapies with NK cells could broaden the potential AFM24 opportunities to treat a range of EGFR-expressing malignancies."

ShowHide Related Items >><<
AFMD Affimed
$9.72 /

+1.85 (+23.51%)

AFMD Affimed
$9.72 /

+1.85 (+23.51%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
  • 13
    Jan
AFMD Affimed
$9.72 /

+1.85 (+23.51%)

Conference/Events
Affimed to hold a conference call » 16:00
04/09/21
04/09
16:00
04/09/21
16:00
AFMD

Affimed

$9.69 /

+1.815 (+23.06%)

Management discusses the…

Management discusses the data presented at the AACR Annual Meeting on a conference call to be held on April 14 at 4:05 pm. Webcast Link

ShowHide Related Items >><<
AFMD Affimed
$9.69 /

+1.815 (+23.06%)

AFMD Affimed
$9.69 /

+1.815 (+23.06%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
  • 13
    Jan
AFMD Affimed
$9.69 /

+1.815 (+23.06%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:54
04/09/21
04/09
12:54
04/09/21
12:54
BA

Boeing

$251.71 /

-3.15 (-1.24%)

, AMZN

Amazon.com

$3,352.25 /

+54.54 (+1.65%)

, CCK

Crown Holdings

$104.06 /

+2.07 (+2.03%)

, AZN

AstraZeneca

$49.80 /

+0.315 (+0.64%)

, JNJ

Johnson & Johnson

$159.95 /

-2.99 (-1.84%)

, AFMD

Affimed

$9.73 /

+1.86 (+23.63%)

, LEVI

Levi Strauss

$25.48 /

+0.465 (+1.86%)

, PRVB

Provention Bio

$8.20 /

-1.52 (-15.64%)

, JKS

JinkoSolar

$38.04 /

-0.82 (-2.11%)

The major averages are…

ShowHide Related Items >><<
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

AFMD Affimed
$9.73 /

+1.86 (+23.63%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

04/09/21 Baird
Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets
03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

04/09/21 Goldman Sachs
Crown Holdings initiated with a Neutral at Goldman Sachs
02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
02/11/21 Barclays
Crown Holdings price target raised to $122 from $103 at Barclays
01/26/21 BMO Capital
Sonoco Products downgraded to Market Perform from Outperform at BMO Capital
AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
AFMD Affimed
$9.73 /

+1.86 (+23.63%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

04/09/21 UBS
Levi Strauss price target raised to $34 from $29 at UBS
04/09/21 Citi
Levi Strauss price target raised to $29 from $25 at Citi
01/27/21 Citi
Levi Strauss price target raised to $25 from $19 at Citi
01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

04/09/21 SVB Leerink
Provention Bio price target lowered to $16 from $26 at SVB Leerink
04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

  • 14
    Jan
  • 13
    Jan
  • 18
    Jun
JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

AFMD Affimed
$9.73 /

+1.86 (+23.63%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

On The Fly
Fly Intel: Pre-market Movers » 08:51
04/09/21
04/09
08:51
04/09/21
08:51
GLSI

Greenwich LifeSciences

$49.29 /

-2.29 (-4.44%)

, AFMD

Affimed

$7.87 /

+0.08 (+1.03%)

, CELC

Celcuity

$14.15 /

-0.1 (-0.70%)

, FUBO

FuboTV

$20.69 /

-0.06 (-0.29%)

, SUNW

Sunworks

$13.91 /

-0.44 (-3.07%)

, JKS

JinkoSolar

$38.86 /

-0.895 (-2.25%)

, TSM

TSMC

$123.46 /

+3.52 (+2.93%)

, IMOS

ChipMOS

$33.62 /

+1.62 (+5.06%)

, GSL

Global Ship Lease

$14.01 /

-0.51 (-3.51%)

, PRVB

Provention Bio

$9.73 /

-0.25 (-2.51%)

Check out this morning's…

ShowHide Related Items >><<
TSM TSMC
$123.46 /

+3.52 (+2.93%)

SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

IMOS ChipMOS
$33.62 /

+1.62 (+5.06%)

GSL Global Ship Lease
$14.01 /

-0.51 (-3.51%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

AFMD Affimed
$7.87 /

+0.08 (+1.03%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

AFMD Affimed
$7.87 /

+0.08 (+1.03%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
CELC Celcuity
$14.15 /

-0.1 (-0.70%)

02/17/21 Craig-Hallum
Celcuity price target raised to $24 from $19 at Craig-Hallum
02/17/21 H.C. Wainwright
Celcuity price target raised to $19 from $18 at H.C. Wainwright
01/28/21 H.C. Wainwright
Celcuity price target raised to $18 from $14 at H.C. Wainwright
12/24/20 Craig-Hallum
Celcuity price target raised to $19 from $16 at Craig-Hallum
FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
03/09/21 Oppenheimer
FuboTV price target lowered to $35 from $45 at Oppenheimer
03/08/21 Alliance Global Partners
Chicken Soup for the Soul initiated with a Buy at Alliance Global Partners
SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
TSM TSMC
$123.46 /

+3.52 (+2.93%)

04/01/21 DA Davidson
Onto Innovation price target raised to $80 from $75 at DA Davidson
03/29/21 Citi
TSMC recent selloff brings 'enhanced buying opportunity,' says Citi
03/25/21 Northland
Northland upgrades AMD to Outperform on Intel's 'strategic faux pas'
03/24/21 Jefferies
Intel price target raised to $59 from $57 at Jefferies
IMOS ChipMOS
$33.62 /

+1.62 (+5.06%)

GSL Global Ship Lease
$14.01 /

-0.51 (-3.51%)

02/12/21
Fly Intel: Top five analyst initiations
02/12/21 Jefferies
Global Ship Lease initiated with a Buy at Jefferies
01/15/21 B. Riley
Global Ship Lease price target raised to $20 from $16 at B. Riley Securities
01/06/21 B. Riley
Global Ship Lease price target raised to $16 from $12 at B. Riley Securities
PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
02/25/21 Chardan
Provention Bio price target lowered to $35 from $40 at Chardan
TSM TSMC
$123.46 /

+3.52 (+2.93%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

IMOS ChipMOS
$33.62 /

+1.62 (+5.06%)

GSL Global Ship Lease
$14.01 /

-0.51 (-3.51%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

  • 09
    Apr
  • 24
    Feb
  • 22
    Jan
  • 14
    Jan
  • 13
    Jan
  • 30
    Dec
  • 18
    Dec
  • 08
    Oct
  • 25
    Sep
  • 18
    Jun
TSM TSMC
$123.46 /

+3.52 (+2.93%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

TSM TSMC
$123.46 /

+3.52 (+2.93%)

SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

PRVB Provention Bio
$9.73 /

-0.25 (-2.51%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

GLSI Greenwich LifeSciences
$49.29 /

-2.29 (-4.44%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

CELC Celcuity
$14.15 /

-0.1 (-0.70%)

AFMD Affimed
$7.87 /

+0.08 (+1.03%)

TSM TSMC
$123.46 /

+3.52 (+2.93%)

SUNW Sunworks
$13.91 /

-0.44 (-3.07%)

JKS JinkoSolar
$38.86 /

-0.895 (-2.25%)

FUBO FuboTV
$20.69 /

-0.06 (-0.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.